CompletedNCT00216528
Symptom remission with long-acting risperidone for schizophrenia
About this title
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
Read the official source — NCT00216528Medication studyAges 18–75
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 527
- Sponsor
- Janssen Korea, Ltd., Korea
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00216528
- Official title
Show the full official title
A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Janssen Korea, Ltd., Korea.
Did this study involve medication?
Yes. The study involved medication, including risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia